{"title":"[Proof of a surgeon's liability].","authors":"Didier Guével","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Pulmonary hypertension due to left heart disease].","authors":"Charles Fauvel, Bouchra Lamia, Nicolas Lamblin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE. Pulmonary hypertension due to left heart disease (PH-LHD) is the leading cause of PH worldwide and is associated with poor short to long-term survival. Its diagnosis (mean pulmonary artery pressure > 20 mmHg with pulmonary artery wedge pressure > 15 mmHg) requires right heart catheterization at rest and afterwards, isolated post-capillary PH (RVP lower 2 WU) has to be separated from combined pre- and post-capillary PH (RVP ≥ 2 WU). Pulmonary vasodilator therapies are not indicated in PH-LHD (grade III) and the main goal is to optimize left heart disease treatment (i.e., heart failure with preserved or reduced ejection fraction or valvular heart disease).</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"50-55"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Treatment of psoriatic arthritis].","authors":"Clementina LópezMedina, Laure Gossec","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>TREATMENT OF PSORIATIC ARTHRITIS. Psoriatic arthritis is a chronic inflammatory rheumatic disease with a heterogeneous clinical presentation, combining peripheral arthritis and skin psoriasis, and frequently enthesitis and dactylitis. The treatment of peripheral arthritis is based on anti-inflammatory drugs, conventional disease-modifying drugs such as methotrexate, and if the disease remains active, targeted disease-modifying drugs (biotherapies, or targeted synthetic drugs). The management of psoriatic arthritis combines treatment of the joints, treatment of the skin psoriasis, and global measures such as physical therapy, patient therapeutic education and lifestyle changes (avoidance of smoking and obesity).</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"7-12"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Lacoste-Palasset, Mitja Jevnikar, Xavier Jaïs
{"title":"[Chronic thromboembolic pulmonary hypertension].","authors":"Thomas Lacoste-Palasset, Mitja Jevnikar, Xavier Jaïs","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Chronic thromboembolic pulmonary hypertension (CTEPH) typically develops after one or more acute pulmonary embolisms (PE). Screening with echocardiography and ventilation-perfusion lung scan is recommended in cases of persistent dyspnea following PE, especially if risk factors for CTEPH are present. However, CTEPH is most often diagnosed during the evaluation of PH. Diagnostic confirmation requires right heart catheterization, which must demonstrate the presence of PH and imaging examinations (CT pulmonary angiography and/or conventional pulmonary angiography) that must reveal characteristic chronic thromboembolic lesions. In addition to effective anticoagulation, which is recommended for all patients, the choice of treatment depends on the location of pulmonary arterial obstructions, the severity of pulmonary hemodynamics, and the presence or absence of comorbidities. Treatment options include pulmonary endarterectomy, medical therapy, and balloon pulmonary angioplasty.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"60-64"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benoît Lechartier, Étienne-Marie Jutant, David Montani
{"title":"[Revised definition and classification of pulmonary hypertension].","authors":"Benoît Lechartier, Étienne-Marie Jutant, David Montani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>REVISED DEFINITION AND CLASSIFICATION OF PULMONARY HYPERTENSION. Pulmonary hypertension (PH) is a manifestation of a diverse group of diseases characterised by elevated mean pulmonary artery pressure (mPAP), measured by right heart catheterisation. The European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension, published in 2022, propose a new haemodynamic definition of PH by lowering the threshold for mPAP to 20 mmHg. Precapillary PH is now defined as mPAP > 20 mmHg associated with normal pulmonary artery wedge pressure (≤ 15 mmHg) and increased pulmonary vascular resistance (> 2 Wood units). These criteria were endorsed during the 7th World Symposium on Pulmonary Hypertension in 2024. The 2022 ESC/ERS guidelines also include a revision of the clinical classification of PH, maintaining the distinction between five entities based on the underlying pathophysiology.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 1","pages":"32-35"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Effects of air pollution on eye health].","authors":"Cécile Delcourt","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>EFFECTS OF AIR POLLUTION ON EYE HEALTH. In addition to its well-known effects on cardio-respiratory health, air pollution could also have an impact on eye health. Indeed, certain air pollutants, especially fine particles and nitrogen dioxide, can enter the bloodstream, triggering oxidative and inflammatory mechanisms involved in the development of the major eye diseases (glaucoma, age-related macular degeneration [AMD], cataracts). Over the past 5 years, some 15 epidemiological studies carried out in Asia, Europe and Canada have consistently shown an increased risk of these diseases in individuals most exposed to air pollution at long term, particularly to fine particles. These results support the lowering of air pollution thresholds recommended by the World Health Organization (WHO) in 2021, which nevertheless continue to be exceeded in most European cities.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"74 9","pages":"947-949"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marc Toutain, Anne-Lise Marais, Anne-Laure Moscone, Antoine Gauthier, Pascale Leconte
{"title":"[Effects of yoga on mental health].","authors":"Marc Toutain, Anne-Lise Marais, Anne-Laure Moscone, Antoine Gauthier, Pascale Leconte","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>EFFECTS OF YOGA ON MENTAL HEALTH. The literature is piling up on the effects of yoga on health in the three most studied areas: on the brain, stress and anxio-depressive symptoms. Following the \"evidence-based practice\" approach, studies highlight the positive effects of yoga practice at these different levels in a variety of adult populations. It also involves identifying the modalities of yoga practice (type, duration and frequency of session, etc.) commonly used in these studies, and ultimately benefiting from scientific evidence of their effect on health that can be used for interventions in the f ield.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"74 9","pages":"1011-1014"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Epilepsy definitions, classifications, and epidemiology].","authors":"Sophie Dupont","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>EPILEPSY DEFINITIONS, CLASSIFICATIONS AND EPIDEMIOLOGY. Epilepsy is the most common neurological disease in the world and the second most common in France. It is defined by the occurrence of 2 unprovoked (or reflex) epileptic seizures more than 24 hours apart, or by the occurrence of an unprovoked (or reflex) epileptic seizure with a recurrence probability of at least 60%. Anti-epileptic treatment can now be started immediately after a first unprovoked epileptic seizure, if risk factors for recurrence are identified, principally the presence of epileptic abnormalities on the electroencephalogram or abnormalities on brain imaging. Epileptic syndromes can either have a characteristic age of onset (newborn, infant, child) or, in the case of other syndromes, a variable age of onset. We are currently witnessing the emergence of epileptic syndromes specific to a given etiology, often genetic.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"74 9","pages":"958-962"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}